Drug Trial Radar · NCT04602754
Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia.
Last checked: Nov 19, 2026Latest source record: Dec 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
228
Planned (sponsor's estimate)
Start
Dec 1, 2023
Primary completion
May 2026
Study completion Sep 2027
Sponsor
- Lead sponsor
- EMSIndustry
- Sponsor type
- Industry
- First posted
- Oct 26, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of Berlim 25/20 association in the treatment of type 2 diabetes mellitus and dyslipidemia.
Conditions
- Dyslipidemia Associated With Type II Diabetes Mellitus
Interventions
BERLIM 25/20 ASSOCIATIONDrug
Berlim 25/20 association coated tablet.
EMPAGLIFLOZIN PLACEBOOther
Empagliflozin placebo coated tablet.
ROSUVASTATIN CALCIUM PLACEBOOther
Rosuvastatin calcium placebo coated tablet.
EMPAGLIFLOZINDrug
Empagliflozin 25 mg coated tablet.
ROSUVASTATIN CALCIUMDrug
Rosuvastatin 20 mg coated tablet.
BERLIM 25/20 ASSOCIATION PLACEBOOther
Berlim 25/20 association placebo coated tablet.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Reduction of glycated hemoglobin levels measured between the first visit and the last visit.Time frame: 120 days
- Percentual reduction of LDL-c levels measured between the first visit and the last visit.Time frame: 120 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Allergisa
Campinas, São Paulo, Brazil · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.